CT引导下氩氦刀联合阿法替尼对肺腺癌患者的临床疗效研究

Clinical efficacy of CT-guided argon-helium knife combined with Afatinib in patients with lung adenocarcinoma

目的探究CT引导下氩氦刀联合化疗或阿法替尼对肺腺癌患者近期疗效与远期生存和复发情况的影响。方法选择2015年1月至2016年9月于固安县人民医院接受一线治疗的晚期肺腺癌患者100例,随机数字法分为对照组(50例)和阿法替尼组(50例),在应用CT引导下氩氦刀冷冻治疗的基础上,对照组采用吉西他滨联合顺铂的化疗方案,阿法替尼组采用口服阿法替尼治疗。比较两组患者的近期疗效、总生存期、无进展生存期,局部复发与远处转移情况以及并发症和不良反应发生率。结果阿法替尼组的客观缓解率、无进展生存期和远处转移时间明显高于对照组(均P<0.05);两组的局部复发时间和并发症发生率差异无统计学意义(P=0.070;P=0.758);阿法替尼组的不良反应发生率明显低于对照组(P<0.05)。结论 CT引导下氩氦刀联合阿法替尼治疗晚期肺腺癌具有较高的疗效和较好的远期生存情况。

Objective To explore the short-term efficacy,long-term survival and recurrence of CT-guided argon-helium knife combined with chemotherapy or Afatinib in patients with lung adenocarcinoma.Methods One hundred patients with advanced lung adenocarcinoma who received first-line treatment in hospital from January 2015 to September 2016 were randomly divided into control group (50 cases) and afatinib group (50 cases).On the basis of CT-guided cryotherapy with argon-helium knife,the control group was treated with Gemcitabine combined with Cisplatin.And the Afatinib group was treated with oral Afatinib.The short-term efficacy,overall survival (OS),progression free survival (PFS),local recurrence and distant metastasis,complications and adverse reactions were compared between the two groups.Results The objective remission rate(ORR),PFS and distant metastasis time of Afatinib group were significantly higher than those of the control group (all P < 0.05).There was no significant difference in the local recurrence time ( P = 0.070) and the incidence of complications ( P = 0.758) between the two groups.The incidence of adverse reactions in the Afatinib group was significantly lower than that in the control group ( P < 0.05).Conclusions CT-guided argon-helium knife combined with Afatinib in the treatment of advanced lung adenocarcinoma has a high efficacy and better long-term survival. Conclusions CT-guided argon-helium knife combined with afatinib in the treatment of advanced lung adenocarcinoma has a high efficacy and better long-term survival.